Quest Magazine

ALS Research: No Smoking Gun

A new meta-analysis combining data from 11 studies has found no connection between variations in genes for paraoxonase (PON) enzymes and an increased risk of developing amyotrophic lateral sclerosis (ALS).

ALS Research: No Smoking Gun

 

A new meta-analysis combining data from 11 studies has found no connection between variations in genes for paraoxonase (PON) enzymes and an increased risk of developing amyotrophic lateral sclerosis (ALS).

“Show me the money!” MDA greenlights grants

At a time when federal and private funds for biomedical research have become scarce, the Muscular Dystrophy Association reasserts its leadership in the fight against muscle diseases by announcing grants to innovative research projects throughout America and in Canada.

“Federal support for the type of work we do has just about dried up, especially in the current economic climate.  Simply put, without the support of MDA, this line of investigation could not be pursued by our lab,” said Eric Schon, researcher at Columbia University Medical Center in New York.

No Smoking Gun

A new meta-analysis combining data from 11 studies has found no connection between variations in genes for paraoxonase (PON) enzymes and an increased risk of developing amyotrophic lateral sclerosis (ALS).

MMD1 Research: Iplex Shows Limited Benefit

The drug Iplex, developed by the Richmond, Va., biopharmaceutical company Insmed, did not improve muscle function, strength or endurance in a phase 2 trial in type 1 myotonic dystrophy (MMD1, or DM1), the company announced June 25, 2009. (See Insmed Announces Results.)

Iplex Shows Limited Benefit in MMD1

The drug Iplex, developed by the Richmond, Va., biopharmaceutical company Insmed, did not improve muscle function, strength or endurance in a phase 2 trial in type 1 myotonic dystrophy (MMD1, or DM1), the company announced June 25, 2009. (See Insmed Announces Results.)

MMD: Insmed Announces Results

RICHMOND, VA., June 25, 2009 - Insmed Inc. (NASDAQ CM: INSM), a biopharmaceutical company, today announced results from its exploratory U.S. Phase II clinical trial evaluating IPLEX™ (mecasermin rinfabate) in patients with myotonic muscular dystrophy (“MMD”).  The randomized, double-blind, placebo-controlled Phase II trial conducted in 13 centers across the U.S.

MD Research: 3-Protein Repair Cluster

Scientists in the United States and Japan have identified a three-protein cluster that reseals damaged muscle-fiber membranes. The findings, published June 5, 2009, in the Journal of Biological Chemistry, could have implications for development of treatments for muscular dystrophies.

ALS 'Lake Link' Tenuous

Recent media reports have raised the question of a possible link between an increased risk of developing amyotrophic lateral sclerosis (ALS) and living near Lake Mascoma in Western New Hampshire.

The Union Leader in New Hampshire and other news outlets have reported that the risk of developing ALS is 25 times higher than average for people living around Lake Mascoma, located in Enfield and Lebanon, N.H. The source of this statistic was not explained.

Three-Protein Repair Cluster Identified

Scientists in the United States and Japan have identified a three-protein cluster that reseals damaged muscle-fiber membranes. The findings, published June 5, 2009, in the Journal of Biological Chemistry, could have implications for development of treatments for muscular dystrophies.




Pages